Anrukinzumab  (Synonyms: IMA-638)

Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

IL-13^[1][2][3].

Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) reduces lung inflammation in cynomolgus monkey model of lung inflammation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

910649-32-0

Liquid

Colorless to light yellow

[Anrukinzumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7.  [Content Brief]

  [2]. Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900.  [Content Brief]

  [3]. Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8.  [Content Brief]